Literature DB >> 11035329

Plasma, urinary, and salivary 8-epi-prostaglandin f2alpha levels in normotensive and preeclamptic pregnancies.

E T McKinney1, R Shouri, R S Hunt, R A Ahokas, B M Sibai.   

Abstract

OBJECTIVE: Our purpose was to measure and compare plasma, urinary, and salivary concentrations of 8-epi-prostaglandin F(2alpha) (8-isoprostane) in women with normotensive pregnancies and the respective concentrations in pregnancies complicated by preeclampsia. STUDY
DESIGN: Plasma, urinary, and salivary 8-isoprostane levels were measured in pregnant women with preeclampsia (n = 40), normotensive pregnant women (n = 20), and nonpregnant women (n = 10). One-way analysis of variance was used to determine significant differences.
RESULTS: Plasma free 8-isoprostane concentrations were increased in women with severe preeclampsia (342 +/- 50 pg/mL), in comparison with nonpregnant women (129 +/- 17 pg/mL) and normotensive pregnant women (150 +/- 11 pg/mL; P =.003, and.0001, respectively). Urinary excretion of 8-isoprostane was slightly but not significantly decreased in preeclampsia (1200 +/- 227 pg/mL), in comparison with urinary excretion in nonpregnant women (1625 +/- 364 pg/mL) and normotensive pregnant women (2149 +/- 432 pg/mL). Salivary concentrations of 8-isoprostane were increased in normotensive women (496 +/- 113 pg/mL), in comparison with nonpregnant women (150 +/- 27 pg/mL) but were not related to preeclampsia (419 +/- 96 pg/mL; P </=.003).
CONCLUSION: Free 8-isoprostane concentrations are increased in the plasma of women with severe preeclampsia. Further studies are warranted to determine whether such increases are caused by an increase in phospholipase A(2) activity, or by lipid peroxidation, or by a decrease in renal excretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035329     DOI: 10.1067/mob.2000.108877

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  14 in total

1.  Oxidative stress and antioxidant defenses in pregnant women.

Authors:  Claudio A M Leal; Maria R C Schetinger; Daniela B R Leal; Vera M Morsch; Aleksandro Schafer da Silva; João F P Rezer; André Valle de Bairros; Jeandre Augusto Dos Santos Jaques
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

Review 2.  Oxidative stress: changes in pregnancy and with gestational diabetes mellitus.

Authors:  Xinhua Chen; Theresa O Scholl
Journal:  Curr Diab Rep       Date:  2005-08       Impact factor: 4.810

3.  Plasma F2-isoprostane class VI isomers at 12-18 weeks of pregnancy are associated with later occurrence of preeclampsia.

Authors:  Jean-François Bilodeau; Shu Qin Wei; Jessica Larose; Karine Greffard; Vanessa Moisan; Francois Audibert; William D Fraser; Pierre Julien
Journal:  Free Radic Biol Med       Date:  2015-05-19       Impact factor: 7.376

Review 4.  Oxidative stress in pregnancy and reproduction.

Authors:  Kate Duhig; Lucy C Chappell; Andrew H Shennan
Journal:  Obstet Med       Date:  2016-05-17

5.  Periodontal disease, oxidative stress, and risk for preeclampsia.

Authors:  Amanda L Horton; Kim A Boggess; Kevin L Moss; James Beck; Steven Offenbacher
Journal:  J Periodontol       Date:  2010-02       Impact factor: 6.993

Review 6.  Assessment of Isoprostanes in Human Plasma: Technical Considerations and the Use of Mass Spectrometry.

Authors:  Yiu Yiu Lee; Jean-Marie Galano; Camille Oger; Claire Vigor; Reversat Guillaume; Jérôme Roy; Jean-Yves Le Guennec; Thierry Durand; Jetty Chung-Yung Lee
Journal:  Lipids       Date:  2016-09-26       Impact factor: 1.880

7.  Impaired renal function and increased urinary isoprostane excretion in Ghanaian women with pre-eclampsia.

Authors:  Paul Winston Tetteh; Charles Antwi-Boasiako; Ben Gyan; Daniel Antwi; Festus Adzaku; Kwame Adu-Bonsaffoh; Samuel Obed
Journal:  Res Rep Trop Med       Date:  2013-06-18

8.  A Proposed Molecular Mechanism of High-Dose Vitamin D3 Supplementation in Prevention and Treatment of Preeclampsia.

Authors:  Piotr Zabul; Michal Wozniak; Andrzej T Slominski; Krzysztof Preis; Magdalena Gorska; Marek Korozan; Jan Wieruszewski; Michal A Zmijewski; Ewa Zabul; Robert Tuckey; Alicja Kuban-Jankowska; Wieslawa Mickiewicz; Narcyz Knap
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

9.  Increased plasma levels of CK-18 as potential cell death biomarker in patients with HELLP syndrome.

Authors:  K John; S Wielgosz; K Schulze-Osthoff; H Bantel; R Hass
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

10.  PPAR Action in Human Placental Development and Pregnancy and Its Complications.

Authors:  Fritz Wieser; Leslie Waite; Christophe Depoix; Robert N Taylor
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.